Novartis has agreed to buy Myricx Bio, a small British oncology company, for up to $1.5bn, adding an early-stage but potentially significant technology to a cancer pipeline the industry keeps racing to expand. The Swiss group will pay $1.1bn upfront, with up to $400m more tied to milestones, in a deal that fits the pattern […]

This story continues at The Next Web